JP Morgan Chase’s Pacira BioSciences PCRX Stock Holding History

JP Morgan Chase’s Portfolio PCRX Stock Details PCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-380,000	Closed	-$16.3M	–	5962
2018 Q4	$16.3M	Hold	380,000	–	–	﹤0.01%	1633
2018 Q3	$18.7M	Buy	380,000 +230,000	+153%	+$9.94M	﹤0.01%	1713
2018 Q2	$4.81M	Buy	+150,000	New	+$5.18M	﹤0.01%	2712
2018 Q1	–	Sell	-108,300	Closed	-$4.94M	–	5565
2017 Q4	$4.94M	Buy	108,300 +98,300	+983%	+$3.9M	﹤0.01%	2685
2017 Q3	$387K	Sell	10,000 -90,000	-90%	-$3.62M	﹤0.01%	3912
2017 Q2	$4.77M	Buy	+100,000	New	+$4.64M	﹤0.01%	2503

Other funds holding PCRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

DPCM

Doma Perpetual Capital Management Miami, Florida $431M AUM 13.21% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

JP Morgan Chase's PCRX Position: Q2 2026 in Review

JP Morgan Chase increased its Pacira BioSciences (PCRX) stake by 44% in Q2 2026, buying an estimated $2.51M and bringing the position to 346,697 shares worth $8.7M. The position accounts for ﹤0.01% of the portfolio, ranked #2930.

JP Morgan Chase first reported a position in PCRX in Q2 2013 and has held it in 53 quarters since. The position peaked at $31.9M in Q2 2014. 254 funds tracked by Wall St. Rank hold PCRX as of Q2 2026.

JP Morgan Chase held 346,697 shares of Pacira BioSciences worth $8.7M as of Q2 2026.
JP Morgan Chase bought 106,328 Pacira BioSciences shares in Q2 2026, an estimated $2.51M.
Pacira BioSciences made up ﹤0.01% of JP Morgan Chase's portfolio in Q2 2026, its #2930 holding.
JP Morgan Chase first reported a position in Pacira BioSciences in Q2 2013 and has held it in 53 quarters since.
JP Morgan Chase's Pacira BioSciences position peaked at $31.9M in Q2 2014.
254 funds tracked by Wall St. Rank held Pacira BioSciences as of Q2 2026.

Based on JP Morgan Chase's 13F filing for Q2 2026, filed 12 Aug 2026.